C. J. Pepine and A. A. Wolff, A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group, Am J Cardiol, vol.84, pp.46-50, 1999.

B. R. Chaitman, Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial, Jama, vol.291, pp.309-325, 2004.

B. R. Chaitman, Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions, Circulation, vol.113, pp.2462-72, 2006.

S. M. Gaffney, Ranolazine, a novel agent for chronic stable angina, Pharmacotherapy, vol.26, pp.135-177, 2006.

C. Antzelevitch, Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties, Circulation, vol.110, pp.904-914, 2004.

Y. Song, J. C. Shryock, L. Wu, and L. Belardinelli, Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes, J Cardiovasc Pharmacol, vol.44, pp.192-201, 2004.

S. Fredj, K. J. Sampson, H. Liu, and R. S. Kass, Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action, Br J Pharmacol, vol.148, pp.16-24, 2006.

A. I. Undrovinas, L. Belardinelli, N. A. Undrovinas, and H. N. Sabbah, Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current, J Cardiovasc Electrophysiol, vol.17, issue.1, pp.169-177, 2006.

D. A. Saint, The cardiac persistent sodium current: an appealing therapeutic target?, Br J Pharmacol, vol.153, pp.1133-1175, 2008.

H. Fraser, Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts, J Mol Cell Cardiol, vol.41, pp.1031-1039, 2006.

G. Hasenfuss and L. S. Maier, Mechanism of action of the new anti-ischemia drug ranolazine, Clin Res Cardiol, vol.97, pp.222-228, 2008.

J. Thireau, J. L. Pasquie, E. Martel, J. Y. Le-guennec, and S. Richard, New drugs vs. old concepts: a fresh look at antiarrhythmics, Pharmacol Ther, vol.132, pp.125-170, 2012.
URL : https://hal.archives-ouvertes.fr/hal-01822221

J. F. Quignard, Voltage-gated calcium channel currents in human coronary myocytes. Regulation by cyclic GMP and nitric oxide, J Clin Invest, vol.99, pp.185-93, 1997.

, Scientific RepoRts |, vol.5

R. H. Cox, Z. Zhou, and T. N. Tulenko, Voltage-gated sodium channels in human aortic smooth muscle cells, J Vasc Res, vol.35, pp.310-317, 1998.

C. Choby, M. E. Mangoni, G. Boccara, J. Nargeot, and S. Richard, Evidence for tetrodotoxin-sensitive sodium currents in primary cultured myocytes from human, pig and rabbit arteries, Pflugers Arch, vol.440, pp.149-52, 2000.

R. Berra-romani, M. P. Blaustein, and D. R. Matteson, TTX-sensitive voltage-gated Na+ channels are expressed in mesenteric artery smooth muscle cells, Am J Physiol Heart Circ Physiol, vol.289, pp.137-182, 2005.

G. Boccara, Regulation of Ca2+ homeostasis by atypical Na+ currents in cultured human coronary myocytes, Circ Res, vol.85, pp.606-619, 1999.

A. Fort, New insights in the contribution of voltage-gated Na(v) channels to rat aorta contraction, PLoS One, vol.4, p.7360, 2009.

W. S. Ho, A. J. Davis, P. S. Chadha, and I. A. Greenwood, Effective contractile response to voltage-gated Na(+ ) channels revealed by a channel activator, Am J Physiol Cell Physiol, vol.304, pp.739-786, 2013.

P. H. Stone, The anti-ischemic mechanism of action of ranolazine in stable ischemic heart disease, J Am Coll Cardiol, vol.56, pp.934-976, 2010.

M. C. Allely, Modulation of alpha 1-adrenoceptors in rat left ventricle by ischaemia and acyl carnitines: protection by ranolazine, J Cardiovasc Pharmacol, vol.21, pp.869-73, 1993.

T. Nieminen, C. A. Tavares, J. R. Pegler, L. Belardinelli, and R. L. Verrier, Ranolazine injection into coronary or femoral arteries exerts marked, transient regional vasodilation without systemic hypotension in an intact porcine model, Circ Cardiovasc Interv, vol.4, pp.481-488, 2011.

M. C. Paredes-carbajal, Effects of Ranolazine on Vasomotor Responses of Rat Aortic Rings, Arch Med Res, 2012.

C. Y. Deng, Effect of ranolazine on rat intrarenal arteries in vitro, Eur J Pharmacol, vol.683, pp.211-217, 2012.

C. Malavaki, Ranolazine enhances nicardipine-induced relaxation of alpha1-adrenoceptor-mediated contraction on isolated rabbit aorta, Acta Cardiol, vol.70, pp.157-62, 2015.

T. Iwamoto, Forefront of Na+ /Ca2+ exchanger studies: molecular pharmacology of Na+ /Ca2+ exchange inhibitors, J Pharmacol Sci, vol.96, pp.27-32, 2004.

S. Sossalla and L. S. Maier, Role of ranolazine in angina, heart failure, arrhythmias, and diabetes, Pharmacol Ther, vol.133, pp.311-334, 2012.

S. Y. Wang and G. K. Wang, Voltage-gated sodium channels as primary targets of diverse lipid-soluble neurotoxins, Cell Signal, vol.15, pp.151-160, 2003.

G. Heusch, The paradox of alpha-adrenergic coronary vasoconstriction revisited, J Mol Cell Cardiol, vol.51, pp.16-23, 2011.

G. K. Wang, J. Calderon, and S. Y. Wang, State-and use-dependent block of muscle Nav1.4 and neuronal Nav1.7 voltage-gated Na+ channel isoforms by ranolazine, Mol Pharmacol, vol.73, pp.940-948, 2008.

C. Antzelevitch, A. Burashnikov, S. Sicouri, and L. Belardinelli, Electrophysiologic basis for the antiarrhythmic actions of ranolazine, Heart Rhythm, vol.8, pp.1281-90, 2011.

H. Khazraei, H. Mirkhani, and A. Purkhosrow, Vasorelaxant effect of ranolazine on isolated normal and diabetic rat aorta: A study of possible mechanisms, Acta Physiol Hung, vol.100, pp.153-62, 2013.

K. G. Digges and R. J. Summers, Effects of yohimbine stereoisomers on contractions of rat aortic strips produced by agonists with different selectivity for alpha 1-and alpha 2-adrenoceptors, Eur J Pharmacol, vol.96, pp.95-104, 1983.

F. Vasconcelos, Effects of voltage-gated Na+ channel toxins from Tityus serrulatus venom on rat arterial blood pressure and plasma catecholamines, Comp Biochem Physiol C Toxicol Pharmacol, vol.141, pp.85-92, 2005.

M. Krajcar and G. Heusch, Local and neurohumoral control of coronary blood flow, Basic Res Cardiol, vol.88, issue.1, pp.25-42, 1993.

E. Barbato, Role of adrenergic receptors in human coronary vasomotion, Heart, vol.95, pp.603-611, 2009.

S. L. Hale, J. C. Shryock, L. Belardinelli, M. Sweeney, and R. A. Kloner, Late sodium current inhibition as a new cardioprotective approach, J Mol Cell Cardiol, vol.44, pp.954-67, 2008.

S. Tzeis and G. Andrikopoulos, Antiarrhythmic properties of ranolazine-from bench to bedside, Expert Opin Investig Drugs, vol.21, pp.1733-1774, 2012.

L. S. Maier and S. Sossalla, The late Na current as a therapeutic target: Where are we?, J Mol Cell Cardiol, vol.61, pp.44-50, 2013.

A. Bocquet, S. Sablayrolles, B. Vacher, and B. Le-grand, F 15845, a new blocker of the persistent sodium current prevents consequences of hypoxia in rat femoral artery, Br J Pharmacol, vol.161, pp.405-420, 2010.

D. Baumgart, Augmented alpha-adrenergic constriction of atherosclerotic human coronary arteries, Circulation, vol.99, pp.2090-2097, 1999.

B. K. Julius, G. Vassalli, L. Mandinov, and O. M. Hess, Alpha-adrenoceptor blockade prevents exercise-induced vasoconstriction of stenotic coronary arteries, J Am Coll Cardiol, vol.33, pp.1499-505, 1999.

R. Venkataraman, L. Belardinelli, B. Blackburn, J. Heo, and A. E. Iskandrian, A study of the effects of ranolazine using automated quantitative analysis of serial myocardial perfusion images, JACC Cardiovasc Imaging, vol.2, pp.1301-1310, 2009.

R. Venkataraman, Effect of ranolazine on left ventricular dyssynchrony in patients with coronary artery disease, Am J Cardiol, vol.110, pp.1440-1445, 2012.

B. R. Chaitman, Efficacy and safety of a metabolic modulator drug in chronic stable angina: review of evidence from clinical trials, J Cardiovasc Pharmacol Ther, vol.9, issue.1, pp.47-64, 2004.

G. Savarese, Effects of ranolazine in symptomatic patients with stable coronary artery disease. A systematic review and metaanalysis, Int J Cardiol, vol.169, pp.262-70, 2013.

R. H. Grimm, . Jr, and J. M. Flack, Alpha 1 adrenoreceptor antagonists, J Clin Hypertens (Greenwich), vol.13, pp.654-661, 2011.

G. V. Petkov, Characterization of voltage-gated calcium currents in freshly isolated smooth muscle cells from rat tail main artery, Acta Physiol Scand, vol.173, pp.257-65, 2001.

A. Gysembergh, Pharmacological manipulation of Ins(1,4,5)P3 signaling mimics preconditioning in rabbit heart, Am J Physiol, vol.277, pp.2458-69, 1999.

E. Youl, Quercetin potentiates insulin secretion and protects INS-1 pancreatic beta-cells against oxidative damage via the ERK1/2 pathway, Br J Pharmacol, vol.161, pp.799-814, 2010.

L. Methven, M. Mcbride, G. A. Wallace, and J. C. Mcgrath, The alpha 1B/D-adrenoceptor knockout mouse permits isolation of the vascular alpha 1A-adrenoceptor and elucidates its relationship to the other subtypes, Br J Pharmacol, vol.158, pp.209-233, 2009.